Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Evaluating copanlisib in combination with nivolumab in patients with RT or transformed NHL

Geoffrey Shouse • 12 Dec 2022
ASH 2022
Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Checkpoint inhibitors Copanlisib Nivolumab

In this video, Geoffrey Shouse, DO, PhD, City of Hope Comprehensive Cancer Center, Duarte, CA, shares some insights into a Phase I study evaluating copanlisib in combination with nivolumab in patients with Richter’s transformation (RT) or transformed non-Hodgkin lymphoma (tNHL; NCT03884998). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Kite Pharma: Speakers Bureau; Beigene Inc USA: Honoraria.

More from Geoffrey Shouse

0:43
The development of a composite comorbidity index to predict CAR-T outcomes in patients with DLBCL
Geoffrey Shouse • 11 Dec 2023
0:58
Novel approaches in Richter's transformation: CAR-T and bispecifics
Geoffrey Shouse • 11 Dec 2023
0:51
Phase I study of copanlisib plus venetoclax in R/R DLBCL
Geoffrey Shouse • 11 Dec 2023
0:58
First-in-human trial of CLN-978, a novel CD19 bispecific antibody, for the treatment of R/R B-NHL
Geoffrey Shouse • 11 Dec 2023

Related Videos

2:04
Salvage treatment options following CAR-T failure in DLBCL
Jaromir Tomasik • 17 Apr 2024
1:55
Exploring first-line CAR-T therapy for the treatment of DLBCL
Wendy Osborne • 22 Apr 2024
3:29
CAR-T therapy as the SoC in 2L LBCL and barriers that remain
Wendy Osborne • 22 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals